Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges
Year: 2016
Type: article
Abstract: Tumor heterogeneity in hepatocellular carcinoma (HCC), such as that found in second primary tumors after curative treatment, synchronous multifocal tumors of different clonality, or intratumor heterogeneity, poses severe challenges for the development and administration of systemic molecular targeted therapies. Various methodologies, including historical DNA ploidy analysis, integrated hepatitis B virus DNA analysis, DNA fingerprinting, and next-generation sequencing technologies, are used to explore tumor heterogeneity in HCC. It is estimated that 30%-60% of recurrent or metastatic tumors harbor clones different from the primary tumor, 22%-79% of synchronous tumors vary clonally, and 12%-66% of single tumors contain intratumor heterogeneity. Substantial intertumor and intratumor heterogeneity renders biomarker identification, which is critical for the development and administration of molecular targeted therapy, challenging when applied to a single tumor biopsy specimen. The use of circulating tumor cells or circulating tumor DNA to evaluate overall tumor heterogeneity may help resolve this problem. This article reviews previous studies of tumor heterogeneity and discusses the implications and future opportunities regarding tumor heterogeneity in HCC.
Source: Liver Cancer
DOI: 10.1159/000367754
Authors: Li-Chun Lu, Chih-Hung Hsu, Chiun Hsu, Ann-Lii Cheng
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Keywords: hepatocellular carcinoma, tumor heterogeneity, intratumoral heterogeneity, intertumoral heterogeneity, clonal evolution, second primary tumors, DNA ploidy, HBV DNA, DNA fingerprinting, next-generation sequencing, circulating tumor cells, circulating tumor DNA, targeted therapy, biomarker discovery
Open Access status: gold
Estimated APC paid: $3,590
OpenAlex ID: W2297822018
